The effect of eldecalcitol on bone mineral density and bone markers for osteoporotic patients with type 2 diabetes. Open label multicenter study.

Trial Profile

The effect of eldecalcitol on bone mineral density and bone markers for osteoporotic patients with type 2 diabetes. Open label multicenter study.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2012

At a glance

  • Drugs Eldecalcitol (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 20 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top